Glaxo Studies Three-In-One Emphysema Medicine to Keep Lead

GlaxoSmithKline Plc, maker of Advair, the world’s best-selling drug for smoker’s cough and asthma, is considering a three-in-one treatment delivered in a single device to stay ahead of competitors such as Novartis AG.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.